TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report

Kei Kunimasa, MD, PhD; Yosuke Hirotsu, PhD; Kenji Amemiya, MSH; Harumi Nakamura, MD, PhD; Kazumi Nishino, MD, PhD; Keiichiro Honma, MD, PhD; Jiro Okami, MD, PhD; Masao Omata, MD, PhD; Toru Kumagai, MD, PhD

JTO Clinical and Research Reports (May 2022)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report

Kei Kunimasa, MD, PhD,
Yosuke Hirotsu, PhD,
Kenji Amemiya, MSH,
Harumi Nakamura, MD, PhD,
Kazumi Nishino, MD, PhD,
Keiichiro Honma, MD, PhD,
Jiro Okami, MD, PhD,
Masao Omata, MD, PhD,
Toru Kumagai, MD, PhD

Affiliations

Kei Kunimasa, MD, PhD: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan; Corresponding Author. Address for Correspondence: Kei Kunimasa, MD, PhD, Department of Thoracic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae Chuoku, Osaka City, Osaka 541-8567, Japan.
Yosuke Hirotsu, PhD: Genome Analysis Center, Yamanashi Central Hospital, Yamanashi, Japan
Kenji Amemiya, MSH: Genome Analysis Center, Yamanashi Central Hospital, Yamanashi, Japan
Harumi Nakamura, MD, PhD: Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan
Kazumi Nishino, MD, PhD: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
Keiichiro Honma, MD, PhD: Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
Jiro Okami, MD, PhD: Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan
Masao Omata, MD, PhD: Genome Analysis Center, Yamanashi Central Hospital, Yamanashi, Japan; The University of Tokyo, Tokyo, Japan
Toru Kumagai, MD, PhD: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan

Journal volume & issue: Vol. 3, no. 5
p. 100305

Abstract

Read online

SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we found a small de novo SCLC component in surgically resected specimens of EGFR-mutated lung adenocarcinoma before EGFR tyrosine kinase inhibitor treatment. By using laser microdissection and whole-exome sequencing, TP53 loss of heterozygosity was found to be possibly involved in SCLC transformation.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords